Quality of Regional Nodal Irradiation Plans in Breast Cancer Patients Across a Large Network-Can We Translate Results From Randomized Trials Into the Clinic?

Autor:	Ling DC; Department of Radiation Oncology, Magee-Women's Hospital, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Moppins BL; Augusta University/University of Georgia Medical Partnership, Athens, Georgia., Champ CE; Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina., Gorantla VC; Division of Hematology/Oncology, Magee-Women's Hospital, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Beriwal S; Department of Radiation Oncology, Magee-Women's Hospital, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania. Electronic address: beriwals@upmc.edu.
Jazyk:	angličtina
Zdroj:	Practical radiation oncology [Pract Radiat Oncol] 2021 Jan-Feb; Vol. 11 (1), pp. e30-e35. Date of Electronic Publication: 2020 Jun 29.
DOI:	10.1016/j.prro.2020.06.007
Abstrakt:	Purpose: Regional nodal irradiation (RNI) improved disease-free survival by 3% to 5% in 2 large randomized trials, but this small absolute advantage relies on accurate contouring and dose delivery. We audited our network to determine compliance on regional nodal coverage, contouring, and dosimetric parameters with respect to accepted guidelines. Methods and Materials: In our network, we have established a clinical pathway for patients with node-positive breast cancer that guides indications for RNI and dosimetric goals. We reviewed records of 183 patients with nodal macrometastases after upfront surgery or involved nodes of any size after neoadjuvant chemotherapy. Radiation treatment plans were examined to determine lymph node volumes treated, whether nodes were contoured, quality of nodal contours, and whether target coverage and normal organ dosimetric constraints were met when RNI was delivered. Results: Despite the presence of macrometastases on sentinel lymph node biopsy, no lymph nodes were treated in 2.2% (4 of 183). Of 179 patients who received nodal irradiation, 18 received radiation to axillary levels 1 and 2 only, and 161 patients received RNI. Overall, regional nodes were not treated despite strong indications in 7.6% (14 of 183). Treated nodes were not contoured for 2.2% (4 of 179), and lymph node contours were unacceptable in 15.4% (27 of 175). Of patients receiving RNI, 14.9% (24 of 161) did not have adequate nodal target volume coverage, mean heart dose was >4 Gy for 3.1% (5 of 161), and lung V20 Gy was >35% for 8.7% (14 of 161). Conclusions: Adherence to indications for regional nodal treatment was high, but nodes were either not contoured or had unacceptable contour quality in 18% of plans, and coverage was inadequate in 15%. Because the small disease-free survival advantage seen in trials may be decreased with these deviations, routine clinical practice requires detailed peer review to fully translate results of clinical trials. (Copyright © 2020 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu